Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down
Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down · Investor's Business Daily

In This Article:

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.